关于贝利尤单抗治疗儿童狼疮性肾炎的一些个人见解  

Some personal advices on belimumab treatment in childhood lupus nephritis

作　　者：张宏文[1] ZHANG Hongwen(Department of pediatrics,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院儿科,北京100034

出　　处：《临床儿科杂志》2025年第2期147-149,156,共4页Journal of Clinical Pediatrics

摘　　要：系统性红斑狼疮(systemic lupus erythematosus,SLE)是儿童最常见的系统性自身免疫性疾病之一,SLE累及肾脏即为狼疮性肾炎(lupus nephritis,LN),LN是影响SLE预后的重要因素之一。贝利尤单抗是一种针对B淋巴细胞刺激因子(BLyS)的重组人IgG1λ单克隆抗体,通过促进B细胞凋亡从而抑制B细胞功能,可改善SLE的反应指数和疾病活动度评分,延缓LN的进展。笔者从儿科临床肾脏医师的角度,探讨了个人对贝利尤单抗治疗儿童LN的一些见解。Systemic lupus erythematosus(SLE)is one of the most common systemic autoimmune diseases in children.The involvement of the kidneys in systemic lupus erythematosus(SLE)is referred to as lupus nephritis(LN),which serves as a critical factor influencing the prognosis of SLE.Belimumab is a recombinant human IgG1λmonoclonal antibody targeting B-lymphocyte stimulator,which inhibits B cell function by promoting B cell apoptosis.Belimumab can improve the response index and disease activity score of SLE,and delay the progression of LN.As a clinical pediatric nephrologist,the author explores some personal advices on the treatment of LN in children with Belimumab.

关 键 词：系统性红斑狼疮 狼疮性肾炎 贝利尤单抗 个人见解 

分 类 号：R725.9[医药卫生—儿科]